Aragen Life Sciences stands to benefit as the biopharma industry looks to derisk its supply chains and shift outsourcing away from China to Indian service providers.
Chief Financial Officer Lucas Montarce said on Monday that the drugmaker’s increase in production capacity from its four future sites in the United States will take years.
The collaboration advances contract development and manufacturing organization services for nanoparticle-based drugs in Taiwan, Japan, and global markets.
Europe depends on Asia for 60% to 80% of its pharmaceutical supply, according to the health ministers, who want to see the European Union adopt the Critical Medicines Act.
